<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370171">
  <stage>Registered</stage>
  <submitdate>10/03/2016</submitdate>
  <approvaldate>30/03/2016</approvaldate>
  <actrnumber>ACTRN12616000403437</actrnumber>
  <trial_identification>
    <studytitle>Stem Cells in Umbilical Blood Infusion for Cerebral Palsy</studytitle>
    <scientifictitle>Safety study of sibling cord blood cell infusion to children with cerebral palsy</scientifictitle>
    <utrn>U1111-1179-9253</utrn>
    <trialacronym>SCUBI-CP</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cerebral palsy</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single intravenous infusion of &gt; 10 million cryopreserved matched sibling cord blood cells. Cells must be in storage at -196degC, with no bacterial contamination, in a TGA accredited cord blood bank.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety
1) Documentation of acute infusion reactions
2) Documentation of any instances of Graft-versus-Host Disease</outcome>
      <timepoint>36 hours, 3 months, 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary analysis of change in gross motor function:
Gross Motor Function Measure (GMFM-66)</outcome>
      <timepoint>3 months, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Chimerism studies to detect the longevity of infused cells:
Copy number deletion analysis of peripheral blood cellular DNA to determine the fraction of donor DNA at each timepoint</outcome>
      <timepoint>1, 4 and 24 hours, 1 week, 1 and 3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary analysis of change in fine motor function:
Quality of Upper Extremity Skills Test (QUEST)
</outcome>
      <timepoint>3 months, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary analysis of change in cognitive function:
Age appropriate cognitive testing</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary analysis of change in quality of life:
Cerebral Palsy Quality of Life (CP-QoL-CHILD)</outcome>
      <timepoint>3 months, 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Diagnosis of any type of CP
2.	CP of any severity
3.	A record of sibling CBU in storage at a TGA accredited private cord blood bank
4.	Ability to travel to one of the trial centres
5.	Ability to participate in assessments
6.	Informed consent by parents</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	presence of progressive neurological disease
2.	known genetic disorder
3.	known brain dysplasia
4.	immune system disorder or immune deficiency syndrome
5.	infectious disease markers showing up on the virology screen
6.	evidence of cord blood unit contamination, or fewer than 10^7 cells/kg body mass
7.	ventilator support
8.	ill health, or if the participants medical condition does not allow safe travel
9.	previous cell therapy
10.	Botulinum toxin A within 3 months before or after infusion
11.	Surgery within 3 months before or after infusion
12.	Cannot obtain parental consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>- Additional exclusion criterion for the first six participants: mild/moderate CP
- Staggered treatments to allow observation between participants</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>7/04/2016</anticipatedstartdate>
    <actualstartdate>7/04/2016</actualstartdate>
    <anticipatedenddate>31/01/2017</anticipatedenddate>
    <actualenddate>6/07/2017</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>25/01/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,NT,QLD,SA,TAS,WA,VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Murdoch Childrens Research Institute</primarysponsorname>
    <primarysponsoraddress>The Royal Children's Hospital
50 Flemington Rd Parkville VIC 3052</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cerebral Palsy Alliance</fundingname>
      <fundingaddress>187 Allambie Rd, Allambie Heights NSW 2100</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Cell Care Australia</fundingname>
      <fundingaddress>42 Corporate Drive, Heatherton VIC 3202</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Cerebral palsy (CP) is the most common physical disability of childhood, affecting 2 per 1000 live births across the world. CP describes permanent non-progressive motor disorders arising from damage to the developing brain. CP is often associated with epilepsy, difficulties in speech, sight, hearing, sensation, perception, behaviour or cognition. There is no cure for CP.

Preclinical studies of different types of stem cells in models of acute brain injury similar to CP have shown significant functional improvement. The variety of stem cells available in umbilical cord blood (UCB), an ethically uncomplicated source of stem cells, has led to a focus on UCB stem cell therapy as a quick-to-clinic option. Previous studies indicate that autologous or unrelated donor UCBC infusion is safe and feasible for children with CP, and may lead to improved motor functioning, but there is no information about the safety and effects of matched sibling cord blood available.

Therefore, this trial will study the safety of infusing matched sibling cord blood cells to children with cerebral palsy. Additionally, we will assess how long the cells remain within the recipient through sensitive chimerism assays, as we hypothesise that the cells may be rejected within 24 hours of infusion. Finally, we will trial the use of a range of outcome measures in this context.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Children's Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Research, Ethics &amp; Governance
The Royal Children's Hospital
50 Flemington Rd, Parkville VIC 3052</ethicaddress>
      <ethicapprovaldate>19/08/2015</ethicapprovaldate>
      <hrec>34210</hrec>
      <ethicsubmitdate>18/09/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/370171-SCUBI-CP Protocol v8 30.08.16.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Dinah Reddihough</name>
      <address>Developmental Disability &amp; Rehabilitation Research
Murdoch Childrens Research Institute
50 Flemington Rd, Parkville VIC 3052</address>
      <phone>+613 9345 5898</phone>
      <fax />
      <email>dinah.reddihough@rch.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kylie Crompton</name>
      <address>Developmental Disability &amp; Rehabilitation Research
Murdoch Childrens Research Institute
50 Flemington Rd, Parkville VIC 3052</address>
      <phone>+613 9936 6756</phone>
      <fax />
      <email>scubi.cp@mcri.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kylie Crompton</name>
      <address>Developmental Disability &amp; Rehabilitation Research
Murdoch Childrens Research Institute
50 Flemington Rd, Parkville VIC 3052</address>
      <phone>+613 9936 6756</phone>
      <fax />
      <email>kylie.crompton@mcri.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kylie Crompton</name>
      <address>Developmental Disability &amp; Rehabilitation Research
Murdoch Childrens Research Institute
50 Flemington Rd, Parkville VIC 3052</address>
      <phone>+613 9936 6756</phone>
      <fax />
      <email>kylie.crompton@mcri.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>